THU0203 Comparison of the retention rate of biological dmards ~ the data from patients with ra who were followed up for over 10 years. (12th June 2018)

• Record Type: Journal Article
• Authors: Fukuda, K.; Matsubara, T.; Funahashi, K.; Itami, T.; Okuda, K.; Hayashi, S.; Sakai, Y.; Kuroda, R.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 321
• Page End: 321
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.6851
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: The use of biological disease modifying anti-rheumatic drugs (bDMARDs) or synthetic DMARDs for the treatment of rheumatoid arthritis (RA) has improved the management of RA and prevented patients with RA from joint destruction. However, there are some cases in which it is difficult to continue the treatment with these medicines due to insufficient therapeutic effect or complications. In Japan, 8 of bDMARDs and 2 of synthetic DMARDs can be used for the treatment of RA. Among them, infliximab (INF) and etanercept (ETN) were applied for RA treatment in 2003 and 2005, respectively, and have been utilised for more than 10 years. Although adalimumab (ADA) and tocilizumab (TCZ) were applied in 2008, RA treatment by ADA and TCZ had been conducted by clinical trials since 2003, and they have also been utilised for more than 10 years. Objectives: In this study, we evaluated the retention rate of these 4 bDMARDs (INF, ETN, ADA, and TCZ) for over 10 years. Methods: RA patients who started the treatment with INF, ETN, ADA, or TCZ before 2007 in Matsubara mayflower hospital and were observed for over 10 years were included in this study. INF was used in the treatment for 111 patients with RA, and 95 out of them were observed for over 10 years (INF group). 95 out of 119 RA patients treated with ETN (ETN group), 24 out of 27 RA patients treated with ADA (ADA group), and 21 out of 25 RA patients treated with TCZ (TCZ group) were included in this study. Kaplan-Meier analysis was applied to determine the differences in the retention rate of these bDMARDs. Results: Kaplan-Meier analysis showed no statistically significant difference in the retention rate of these bDMARDs. The retention rate of INF group and TCZ group decreased with time and was 10.5% and 33.3% at the final survey in November 2017, respectively. That of ETN group and ADA group plateaued at 9 years after the start of treatment and was 22.1% and 8.33% at the final survey, respectively. Conclusions: In this study, there was no statistically significant difference in the retention rate of these bDMARDs. The retention rate of over 10 years was the highest in TCZ group and the lowest in ADA group. The rate of INF group and TCZ group continued to decrease, and that of ETN group and ADA group was almost constant after 9 years from the start of treatment. Disclosure of Interest: None declared